Aptose completes US$20M share purchase agreement with Aspire Capital
May 10, 2019
20.00 Million USD
On May 10, 2019, Aptose Biosciences Inc. completed its previously announced share purchase agreement with Aspire Capital Fund, LLC whereby Aspire will purchase up to US$20 million of Aptose's common shares, at Aptose's request, for up to 30 months. The agreement also limits the amount of Aptose's issued and outstanding shares that Aspire can own at one time to 9.99% as well as limits the amount of Aptose's shares that can be issued to 19.99%. Aptose will issue 171,428 shares to Aspire as a commitment fee.
Aptose is a San Diego and Toronto-based biopharmaceutical company focused on the discovery, research and development of anti-cancer therapies.
Aspire is a Chicago-based investment fund managed by Aspire Capital Partners, LLC that specializes in open market and direct equity investments in the healthcare and technology sectors.
McCarthy Tétrault LLP advised Aptose with a team led by Charles-Antoine Soulière that included Felipe Díaz Villegas and Vincent Laurin.